AJCN EB Program 2010 Early Registration
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hsu, I. R
Right arrow Articles by Bergman, R. N
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hsu, I. R
Right arrow Articles by Bergman, R. N
Agricola
Right arrow Articles by Hsu, I. R
Right arrow Articles by Bergman, R. N
American Journal of Clinical Nutrition, Vol. 86, No. 3, 867S-871S, September 2007
© 2007 American Society for Nutrition


Metabolic Syndrome and the Onset of Cancer

Metabolic syndrome, hyperinsulinemia, and cancer1,2,3

Isabel R Hsu, Stella P Kim, Morvarid Kabir and Richard N Bergman

1 From the Department of Physiology and Biophysics, University of Southern California, Los Angeles, CA

ABSTRACT

The term metabolic syndrome describes the association between obesity, insulin resistance, and the risk of several prominent chronic diseases, including cancer. The causal link between many of these components remains unexplained, however. What is clear are the events that precede the development of the syndrome itself. In animal models, a fat-supplemented diet causes 1) lipid deposition in adipose depots, 2) insulin resistance of liver and skeletal muscle, and 3) hyperinsulinemia. One hypothesis relating fat deposition and insulin resistance involves enhanced lipolysis in the visceral depot, which leads to an increase in free fatty acid (FFA) flux. Increased mass of stored lipid and insulin resistance of visceral adipocytes favors lipolysis. Additionally, hypersensitivity of visceral adipose cells to sympathetic nervous system stimulation leads to increased lipolysis in the obese state. However, little evidence is available for enhanced plasma FFA concentrations in the fasting state. We measured FFA concentrations over a 24-h day in obese animals and found that plasma FFAs are elevated in the middle of the night, peaking at 0300. Therefore, it is possible that nocturnal lipolysis increases exposure of liver and muscle to FFAs at night, thus causing insulin resistance, which may play a role in hyperinsulinemic compensation to insulin resistance. Nocturnal lipolysis secondary to sympathetic stimulation may not only cause insulin resistance but also be responsible for hyperinsulinemia by stimulating secretion and reducing clearance of insulin by the liver. The resulting syndrome—elevated nocturnal FFAs and elevated insulin—may synergize and increase the risk of some cancers. This possible scenario needs further study.

Key Words: Metabolic syndrome • obesity • insulin resistance • hyperinsulinemia • free fatty acids • nocturnal lipolysis • sympathetic nervous system • cancer




This article has been cited by other articles:


Home page
Am. J. Clin. Nutr.Home page
J.-R. Zhou, G. L Blackburn, and W A. Walker
Symposium introduction: metabolic syndrome and the onset of cancer
Am. J. Clinical Nutrition, September 1, 2007; 86(3): 817S - 819S.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by The American Society for Nutrition